July 13, 2020

The Niche

Knoepfler lab stem cell blog

Ocata Therapeutics

1 min read

What new papers and news in the stem cell sphere caught your eye? Here are some recent items that seem notable to me. Diabetes relief in mice by glucose-sensing insulin-secreting human α-cells. This paper reports cellular reprogramming to insulin-producing cells in mice. They reprogrammed α-cells with Pdx1 and MafA proteins. ‘Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease’ in Nature Neuroscience. Using IPS cells for insights. “What open chromatin features predict pluripotency?” asked and answered by the authors of this review …Read More

4 min read

What were the top 10 stem cell stories of the year? What were the biggest news and science headlines in the stem cell field in 2015, whether good or bad? Below are mine. What are your top 10 stem cell stories of the past year? Let us know in the comments. Organoids explode. Stem cell-based mini-organs (organoids) have exploded in terms of impact in the last couple years. 2015 had many examples of these super cool human organs in a dish made from stem …Read More

1 min read

I asked Ocata CSO, Bob Lanza, for a comment on the big news of the acquisition of the company by Astellas. Here’s what he had to say: “I can say that this is an exciting time for regenerative medicine.  The merger should greatly accelerate the pace of discovery, and, I hope, lead to treatments for a long list of diseases.” The day after hearing the news, I myself feel a bit more optimistic that Astellas will continue this important work and help patients with …Read More

2 min read

Bombshell news in the stem cell field as Ocata Therapeutics (OCAT; formerly Advanced Cell Technology or ACT) is reportedly to be acquired by Astellas Pharma, Inc. The offer for purchase of OCAT will be $8.50/share or almost $380 million. For more details see this detailed PDF from Astellas. This quote on the deal form Ocata: “Paul Wotton, Ph.D., President and CEO, Ocata said, “I am impressed by the vision and commitment of Astellas and believe that with their global resources behind our regenerative platform, patients …Read More